Citations

Clear

1417 citation(s) found for "Simon, FM".

ELSO 2025 Narrative Guideline on ECMO Training and Continuing Education
Han, Peggy , Shekar, Kiran, Ramanathan, Kollengode, Brio, Jordi Riera del, Diaz, Rodrigo, Alfoudri, Huda , Ramanan, Raj , Sin, Simon W. C., Vercaemst, Leen , Friedrich, Tammy, Said, Ahmed, Zakhary, Bishoy, Riera, Jordi , Moore, Elizabeth A , Riera, Jordi , Moore, Elizabeth A. , Shekar, Kiran , Ramanathan, Kollengode R. , Puślecki, Mateusz , Sin, Wai Ching , Roeleveld, Peter Paul , Alinier, Guillaume , Zakhary, Bishoy

Mayo Clinic

ASAIO Journal | March 30, 2026 | Volume: 72 | Issue: 4 | Pages: 274-283

10.1097/mat.0000000000002686 | PMID 41910607 Get It

Disclaimer: These guidelines are intended for educational use to build the knowledge of physicians and other health professionals in assessing the conditions and managing the treatment of patients undergoing extracorporeal life support (ECLS)/ECMO and describe what are believed to be useful and safe practice for ECLS and ECMO. The aim of clinical guidelines was to help clinicians to make informed decisions about their patients. However, adherence to a guideline does not guarantee a successful outcome. Healthcare professionals must make their own treatment decisions about care on a case-by-case basis, after consultation with their patients, using their clinical judgment, knowledge, and expertise. These guidelines do not take the place of physicians’ and other health professionals’ judgment in diagnosing and treatment of patients. These guidelines are not intended to and should not be interpreted as setting a standard of care or being deemed inclusive of all proper methods of care nor exclusive of other methods of care directed at obtaining the same results. The ultimate judgment must be made by the physician and other health professionals and the patient considering all the circumstances presented by the individual patient, and the known variability and biologic behavior of the clinical condition. These guidelines reflect the data at the time the guidelines were prepared; the results of subsequent studies or other information may cause revisions to the recommendations in these guidelines to be prudent to reflect new data, but ELSO is under no obligation to provide updates. In no event will ELSO be liable for any decision made or action taken in reliance upon the information provided through these guidelines.
Clinical Criteria for the Definition of Refractory Septic Shock: A Joint Delphi Consensus from the Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM)
Myatra, Sheila Nainan , Dugar, Siddharth , Russell, Lene , Delamarre, Louis , Sharif, Sameer , Chew, Michelle S. , Gong, Michelle N. , Hernández, Glenn , Martín‐Loeches, Ignacio , Dünser, Martin W., Einav, Sharon , Hamzaoui, Olfa, Frazee, Erin N. , Busse, Laurence W. , Deutschman, Clifford S. , Holder, Andre L. , Nazer, Lama , Nunnally, Mark , Rincon, Teresa , Seymour, Christopher W. , Besen, Bruno Adler Maccagnan Pinheiro , Finfer, Simon , Machado, Flávia Ribeiro , Mer, Mervyn , Young, Paul J. , Khanna, Ashish , Dugar, Siddharth , Wieruszewski, Patrick M , Russell, Lene , Evans, Laura , Delamarre, Louis , Sharif, Sameer , Chew, Michelle S , Gong, Michelle Ng , Hernández, Glenn , Schorr, Christa , Lakbar, Ines , Smith, Susan E , Martin-Loeches, Ignacio , Annane, Djillali , Balik, Martin , Cecconi, Maurizio , De Backer, Daniel , Donadello, Katia , Einav, Sharon , Ferrer, Ricard , Juffermans, Nicole , Hamzaoui, Olfa , Landoni, Giovanni , Levy, Bruno , McKenzie, Cathrine , Monnet, Xavier , Ostermann, Marlies , Spies, Claudia D , Singer, Mervyn , Theodorakopulou, Maria , Topeli, Arzu , Frazee, Erin N , Bauer, Seth R , Busse, Laurence W , Coopersmith, Craig M , Deutschman, Clifford , Holder, Andre L , Kamaleswaran, Rishikesan , Legrand, Matthieu , Martin, Greg S , Maves, Ryan C , Nazer, Lama , Nunnally, Mark E , Prescott, Hallie C , Rincon, Teresa , Sacha, Gretchen , Seymour, Chris W , Arabi, Yaseen M , Besen, Bruno Amp , Cavalcanti, Alexandre Biasi , Deane, Adam M , Finfer, Simon , Hammond, Naomi , Ibarra-Estrada, Miguel , Kattan, Eduardo , Kotani, Yuki , Machado, Flavia R , Ospina-Tascón, Gustavo A , Mer, Mervyn , Young, Paul J , Rochwerg, Bram , Khanna, Ashish K , Léone, Marc , Wieruszewski, Patrick M. , Smith, Susan , Backer, Daniel De , Dünser, Martin W. , Lévy, Bruno , McKenzie, Cathrine , Ostermann, Marlies , Spies, Claudia , Kamaleswaran, Rishikesan , Legrand, Matthieu , Martin, Greg S. , Maves, Ryan C. , Prescott, Hallie C. , Arabi, Yaseen M. , Deane, Adam M. , Hammond, Naomi

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 5 | Pages: 1073-1091

10.1097/ccm.0000000000007124 | PMID 41873857 Get It

OBJECTIVE: A definition of refractory septic shock is necessary to guide diagnosis, management, prognostication, research, and future guidelines for this most severe form of the disease. We sought to achieve consensus on clinical criteria that would be used to define refractory septic shock. DESIGN: Review of literature, expert panel position statements, and Delphi rounds with an international expert group. SETTING: Consensus was defined as having at least 75% of panellists in agreement or disagreement on the three highest or lowest levels of a 7-point Likert scale or based on responses to single- or multiple-choice questions, respectively. SUBJECTS: A panel of multinational, multiprofessional and multidisciplinary critical care experts assembled by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine (57 invitations and 56 participants). MEASUREMENTS AND MAIN RESULTS: A five-round Delphi process was conducted for consensus and stability. The steering committee proposed 34 statements, and five of them were rejected by panel experts after round 2. Among 29 statements selected from eight domains, consensus was reached for 13. The panel agreed on the need for a comprehensive consensus set of clinical criteria for refractory septic shock. Markers of organ dysfunction (75%, 2 rounds), tissue perfusion (91.1%, 2 rounds) including lactate (94.6%, 2 rounds) and capillary refill time (76.8%, 2 rounds), assessment of fluid-responsiveness after initial resuscitation (92.9%, 5 rounds), and use of vasoactive drugs at norepinephrine equivalents greater than 0.5 µg/kg/min (75.0%, 3 rounds), were selected as clinical criteria of refractory septic shock. The use of critical care ultrasound (CCUS) (92.9%, 3 rounds) was the single diagnostic modality that reached a consensus-based agreement. CONCLUSIONS: A consensus for 13 criteria to frame the definition of refractory septic shock was reached. Refractory septic shock is characterised by persistently elevated lactate concentrations and or prolonged capillary refill time in patients with septic shock who are fluid unresponsive, require a norepinephrine base equivalent dose greater than 0.5 micrograms per kilogram per minute, and undergo CCUS assessment when mixed shock is suspected.
1534: ICH-CARE: ICH-INTEGRATED CARE FOR ACCELERATED RESPONSE TO HEMORRHAGE
Peacock, Sarah, Mooney, Lesia, Freeman, David, Simon, Lesie, English, Stephen, Huang, Joesphine, Ng, Lauren, Peacock, Sarah

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 3S | Pages: No page available

10.1097/01.ccm.0001188132.80350.7a Get It

Circulating levels of insulin‐like growth factor I ( IGF ‐I) and risk of multiple myeloma: An observational and Mendelian randomisation study
Benavente, Yolanda, Hermosa, Sara, Clay‐Gilmour, Alyssa, Brown, Elizabeth , Hofmann, Jonathan N., Rothman, Nathaniel, Lan, Qing, Berndt, Sonja I., Albanes, Demetrius, Purdue, Mark, Chanock, Stephen J., Norman, Aaron, Kumar, Shaji K., Vachon, C M, Novak, Anne J. , Ghesquieres, Herve, Bracci, Paige M., Holly, Elizabeth, Griffin, Rosalie G., Vermeulen, Roel , Hjalgrim, Henrik, Smedby, Karin Ekström, Cheah, Simon , Monnereau, Alain, Arslan, Alan, Zhang, Yawei, Camp, Nicola J., Sborov, Douglas W., Ziv, Elad , Joseph, Vijai, Teras, Lauren R., Patel, Alpa V. , Vajdic, Claire M., Cocco, Pierluigi, Alemany, Laia, McKay, James, Casabonne, Delphine , Monnereau, Alain , Brown, Elizabeth E , Machiela, Mitchell J , Slager, Susan L , Cerhan, James R , Rajkumar, S Vincent , Novak, Anne J , Habermann, Thomas , Salles, Gilles A , Hildebrandt, Michelle A T , Jayasekara, Harindra , Cheah, Simon , Kane, Eleanor , Guilloteau, Adrien , Casabonne, Delphine , Ziv, Elad , Benavente, Yolanda , Papadimitriou, Nikos , Clay‐Gilmour, Alyssa , Hofmann, Jonathan N. , Rothman, Nathaniel , Lan, Qing , Berndt, Sonja I. , Albanes, Demetrius , Machiela, Mitchell J. , Chanock, Stephen Jacob , Bhatti, Parveen , Cozen, Wendy , Slager, Susan L. , Cerhan, James R. , Rajkumar, S. Vincent , Habermann, Thomas M. , Link, Brian K. , Salles, Gilles , Ghesquières, Hervé , Bracci, Paige M. , Waller, Rosalie G. , Hildebrandt, Michelle A.T. , Kolijn, Pieter Martijn , Hjalgrim, Henrik , Jayasekara, Harindra , Chen, Yu , Camp, Nicola J. , Sborov, Douglas W. , Osman, Afaf E.G. , Vivo, Immaculata De , Teras, Lauren R. , Kane, Eleanor , Vajdic, Claire M. , Alemany, Laia, Sáinz, Juan , McKay, James, Birmann, Brenda M.

Mayo Clinic

British Journal of Haematology | March 24, 2026 | Volume: 208 | Issue: 6 | Pages: 1942-1953

10.1111/bjh.70444 | PMID 41873017 Get It

Summary Evidence for an association between insulin‐like growth factors (IGF) and multiple myeloma (MM) is inconsistent. We examined total IGF‐I concentrations and risk of MM by combining baseline serological data among UK Biobank participants ( n = 444 187; 732 incident MM) with a two‐sample Mendelian randomisation (MR) analysis using identified genetic variants associated with circulating total IGF‐I and IGF‐binding protein 3 (IGFBP‐3) in the InterLymph consortium (2434 MM and their 2567 controls). Finally, additional lymphoid neoplasm (LN) subtypes were included for comparison with the main hypothesis. Circulating IGF‐I level was positively associated with MM risk Hazard ratio‐HR‐per one standard deviation‐SD‐increase (HR 1‐SD = 1.11, 95% confidence interval [CI]: 1.01–1.22; p ‐value = 0.03), especially closer to diagnosis. Genetically inferred IGF‐I levels were associated with increased MM risk (odds ratio [OR] = 1.27, 95% CI: 1.05–1.54) but not with any other LNs. Genetically inferred IGFBP‐3 levels showed no associations with any LN evaluated. Corroborating previous findings, in a secondary analysis, IGF‐I levels were associated with the risk of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) in males with higher body mass index (HR 1‐SD in obese male = 1.36, 95% CI: 1.14–1.61). Our serological and MR analyses suggest a contributing role of IGF‐I in the susceptibility of MM; the CLL/SLL findings warrant further investigation considering sex‐specific adiposity.
Abstract B032: Drug and single-cell gene expression integration identifies heterogeneity-aware synergistic combinations for glioblastoma
Suter, Robert K. , Jermakowicz, Anna, Veeramachaneni, Rithvik, D'Antuono, Matthew, Zhang, L.G., Chowdary, Rishika , Kaeppeli, Simon , Sharp, Madison, Palwai, Pravallika, Stathias, Vasileios , Baker, Grace, Ruiz, Luz , Walters, Winston, Cepero, Maria, Reilly, Edward B. , Oleksijew, Anatol, Anderson, Mark G. , Williams, Sion Ll., Komotar, Ricardo J., Fuente, Macarena I. de la , Stein, Gregory , Wojcinski, Alexandre , Schürer, Stephan C. , Ayad, Nagi , Jermakowicz, Anna M. , D’Antuono, Matthew , Palwai, Pravallika, Cepero, Maria L., Burgenske, Danielle M. , Ivan, Michael E , Stein, Gregory, Kesari, Santosh , Sarkaria, Jann N. , Ayad, Nagi G.

Mayo Clinic

Cancer Research | March 23, 2026 | Volume: 86 | Issue: 6_Supplement | Pages: B032-B032

10.1158/1538-7445.brain26-b032 Get It

Abstract Glioblastoma (GBM) remains the most common and lethal adult malignant primary brain cancer with few treatment options. A significant issue hindering GBM therapeutic development is intratumor heterogeneity and plasticity. GBM tumors contain neoplastic cells within a fluid spectrum of diverse transcriptional states. Identifying effective therapeutics requires a platform that predicts the differential sensitivity and resistance of these states to various treatments. Here, we develop scFOCAL (Single-Cell Framework for -Omics Connectivity and Analysis via L1000), to quantify the cellular drug sensitivity and resistance landscape. Using single-cell RNA sequencing of newly diagnosed and recurrent GBM tumors, we identify compounds from the LINCS L1000 database with transcriptional response signatures selectively discordant with distinct GBM cell states, and leverage this capability to predict combination synergy. We validate the significance of these findings in vitro, ex vivo, and in vivo, and use the Olig2 inhibitor CT-179 as a reference drug to identify additional small molecules that would maximize the cell-drug discordance across the GBM transcriptional landscape. Our analysis leads to the combination of Olig2 inhibition with treatment with Depatux-M, of with which we demonstrate synergy in vivo. Our studies suggest that scFOCAL identifies cell states that are sensitive and resistant to targeted therapies in GBM using a measure of cell and drug connectivity, which can be applied to identify new synergistic combinations. Citation Format: Robert K. Suter, Anna M. Jermakowicz, Rithvik Veeramachaneni, Matthew D'Antuono, Longwei Zhang, Rishika Chowdary, Simon Kaeppeli, Madison Sharp, Pravallika Palwai, Vasileios Stathias, Grace Baker, Luz Ruiz, Winston Walters, Maria Cepero, Danielle Burgenske, Edward B. Reilly, Anatol Oleksijew, Mark G. Anderson, Sion Ll. Williams, Michael E. Ivan, Ricardo J. Komotar, Macarena I. De La Fuente, Gregory Stein, Alexandre Wojcinski, Santosh Kesari, Jann N. Sarkaria, Stephan C. Schürer, Nagi G. Ayad. Drug and single-cell gene expression integration identifies heterogeneity-aware synergistic combinations for glioblastoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Brain Cancer; 2026 Mar 23-25; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(6_Suppl):Abstract nr B032.
Translating AI research into reality: summary of the 2025 voice AI Symposium and Hackathon
Cruz, Samantha Salvi, Toghranegar, Jamie , MacDonald, Bob, Speights, Marisha, Noufi, Camille , Fagherrazi, Guy, Blatter, Alden, Arienzo, Arianna, Baur, Sebastien , Wetstone, Katie , Peller, Julian, Au, R., Botha, Hugo, Lahav, Amir, Hemmerling, Daria , Anibal, James, Coleman, Oita C, Gallois, Hortense , Martinez, Sophia Avila, Mahapatra, Nihar R. , Sara, Jaskanwal Deep Singh , Mathur, Aarush, Patel, Rupal , Zieliński, Konrad , Lerner-Ellis, Jordan, Cong, Yan , Ngo, Hoan, Talkar, Tanya , Hale, Greg, Comito, Keith, Ghosh, Satrajit, Watts, Stephanie, Powell, Maria, Bélisle-Pipon, Jean-Christophe, Krussel, Andrea, Mahapatra, Ishaan, Bahr, Ruth Huntley , Kostelnik, Cynthia, Dorsey, Katie, John, MyVan, Curp, Kathleen, Rameau, Anaïs, Bensoussan, Yaël , Singh Sara, Jaskanwal Deep, Hemmerling, Daria , Cruz, Samantha Salvi, Malin, Bradley , Mehra, Tarun , Speights, Marisha L., Fossat, Yan , Cummins, Nicholas , Elbeji, Abir , Gelbard, Alexander , Au, Rhoda , Botha, Hugo, Lahav, Amir, Catania, Fabio , Saha, Shumit , Kourtis, Lampros C , Lerner‐Ellis, Jordan P. , Watts, Stephanie, Bedrick, Steven , Belisle-Pipon, Jean-Christophe , Krussel, Andrea, Mahapatra, Ishaan , Hanna, Karim , Rameau, Anais

Mayo Clinic

Frontiers in Digital Health | March 16, 2026 | Volume: 8 | Issue: No issue available | Pages: No page available

10.3389/fdgth.2026.1754426 | PMID 41918982 Get It

The 2025 Voice AI Symposium represented a transition from conceptual research to clinical implementation in vocal biomarker science. Hosted by the NIH-funded Bridge2AI-Voice consortium, the meeting convened global experts to address the methodological, ethical, and translational challenges of integrating voice-based artificial intelligence (AI) into healthcare. This mini-review synthesizes symposium insights across six domains: multimodal integration, FAIR (Findable, Accessible, Interoperable, Reusable) and CARE (Collective Benefit, Authority to Control, Responsibility, Ethics) data governance, clinical translation, interdisciplinary training, and cross-sector innovation. Research presented demonstrated voice as a latent, multimodal biomarker reflecting neurological, cardiopulmonary, and psychological states, while discussions emphasized ethical data practices and human-centered design. The implementation-focused panels underscored the importance of workflow alignment and usability for adoption in real-world care. Collectively, the symposium reflects a field advancing toward translational readiness and ethical accountability, positioning voice AI as a scalable, inclusive tool for next-generation healthcare.
The Complexities of Reoperative Metabolic and Bariatric Surgery–A Retrospective Review of Outcomes at a Single Large Institution
Bocchinfuso, Sara , Abedalqader, Tala, Ghazal, Nour El, Laplante, Simon , Mehta, Kabir , Ghanem, Omar M., Ghazal, Nour El , Jawhar, Noura , El Ghazal, Nour , Sample, Jack W. , Abedalqader, Tala , Ghanem, Omar M.

Mayo Clinic

Surgical Laparoscopy, Endoscopy & Percutaneous Techniques | March 9, 2026 | Volume: 36 | Issue: 3 | Pages: No page available

10.1097/sle.0000000000001455 | PMID 41800697 Get It

Background: Reoperative metabolic and bariatric surgery (MBS), consisting of revision and conversion surgery, carries higher morbidity and mortality compared with primary procedures, yet robust long-term data are limited. Methods: A retrospective review was conducted of all patients 18 years of age or older who underwent first-time reoperative MBS between 2000 and 2024 at a single large quaternary referral center. Data were stored securely and analyzed in R (v4.4.2) using standard descriptive statistics and group tests ( t tests/Wilcoxon/Kruskal-Wallis; χ²/Fisher). Sparse late-complication data precluded pairwise tests. Results: Three hundred sixty patients, 86% female, mean age 50 years, underwent reoperative MBS. Conversion to Roux-en-Y gastric bypass (49%) was the most common surgery. The majority were performed for weight recidivism (37%). Length of stay, estimated blood loss, length of surgery, complication rates, readmission rates, and reintervention rates varied by type of reoperative MBS performed and indication. Most early complications were Clavien-Dindo 2, and most late complications were Clavien-Dindo 3b for all approaches. There was one procedure-related death in the study following an open conversion. Conclusion: In this 24-year single-center cohort, weight recidivism was the most frequent indication for reoperation and was associated with improved perioperative outcomes and durable long-term weight loss. As the landscape of bariatric surgery continues to evolve, we recommend early referral to centers with reoperative MBS expertise.
Rucaparib vs docetaxel (DTX) or second-generation androgen receptor pathway inhibitor (ARPI) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations based on
Fizazi, Karim , Chowdhury, Simon, Ryan, Charles J. , Villanueva, Noemí, Caffo, O., Chakmakjian, Carl, Ernst, D. Scott, Feyerabend, Susan , Font, Albert , Ganju, Vinod, Kushnir, Igal , MADSEN, CHRISTINE VESTERGAARD, Borrow, Jen, Ong, Valerie Shu Fei., Ostler, Peter , Reaume, Martin Neil , Bryce, Alan H. , Villanueva, Noemi , Caffo, Orazio , Ernst, D. Scott, Ganju, Vinod, Hajdenberg, Julio J.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 46-46

10.1200/jco.2026.44.7_suppl.46 Get It

46 Background: Primary results from the randomized, multicenter, open-label, phase 3 TRITON3 (NCT02975934) study demonstrated that rucaparib significantly improved radiographic progression-free survival (rPFS) vs physician’s choice of DTX or an ARPI. ECOG PS is used as a predictor of prostate cancer survival. In this post hoc analysis, we report results from the BRCA1/2 subgroup of pts stratified by ECOG PS. Methods: Pts with disease progression after 1 prior second-generation ARPI in any setting were randomized 2:1 to rucaparib 600 mg BID or physician’s choice of DTX or ARPI (abiraterone acetate or enzalutamide). Primary endpoint was rPFS by independent radiology review (IRR). Objective response rate (ORR) for pts with measurable disease and overall survival (OS) were key secondary endpoints. Crossover from physician’s choice to rucaparib was allowed after radiographic progression was confirmed by IRR. Data cutoff was August 25, 2022. Results: Of 302 pts in the BRCA1/2 population, 147 had an ECOG status of 0 (97 rucaparib; 50 physician’s choice) and 155 had ECOG 1 (104 rucaparib; 51 physician’s choice). Baseline characteristics and demographics were generally similar between arms for pts in the ECOG 0 and ECOG 1 groups. Median rPFS favored rucaparib vs physician’s choice for pts with ECOG 0 (11.4 vs 8.2 months; HR, 0.48 [95% CI, 0.30-0.76]) and ECOG 1 (10.9 vs 6.1 months; HR, 0.48 [95% CI, 0.31-0.74]) (Table). Additionally, rPFS favored rucaparib for ECOG 0 and ECOG 1 including those whose prespecified physician’s choice was ARPI or docetaxel (Table). The confirmed ORR (95% CI) of rucaparib vs physician’s choice for ECOG 0 was 54% (37%–69%) vs 16% (3%–40%); the ORR for ECOG 1 was 37% (22%–53%) vs 18% (5%–40%), respectively. Median OS was similar between arms for rucaparib or physician’s choice; median OS was 23.7 vs 21.7 months (HR, 0.91 [95% CI, 0.61–1.37]) for ECOG 0 and 21.8 vs 20.4 months (HR, 0.85 [95% CI, 0.58–1.24]) for ECOG 1. Conclusions: Rucaparib improved rPFS and ORR in pts with BRCA-mutated prostate cancer with an ECOG PS of 0 or 1. OS was similar for these groups in both arms. These data support rucaparib as a treatment option for pts with BRCA-mutated mCRPC, whether ECOG 0 or 1. Clinical trial information: NCT02975934 . Median rPFS in patients in the ECOG 0 and ECOG 1 groups. Rucaparib, n Physician’s choice, n rPFS Rucaparib, median months rPFS Physician’s choice, median months HR (95% CI) rPFS, ECOG 0 97 50 11.4 8.2 0.48 (0.30–0.76) rPFS, ECOG 1 104 51 10.9 6.1 0.48 (0.31–0.74) rPFS, physician’s choice ARPI, ECOG 0 51 24 11.2 5.6 0.42 (0.22–0.78) rPFS, physician’s choice docetaxel, ECOG 0 46 26 11.5 8.8 0.49 (0.24–0.98) rPFS, physician’s choice ARPI, ECOG 1 52 17 11.2 4.5 0.33 (0.16–0.68) rPFS, physician’s choice docetaxel, ECOG 1 52 34 10.7 7.1 0.59 (0.34–1.01)